绿灯激活双作用Pt(IV) 产药具有增强的PDT活动
Daniil Spector1, Vladislav Bykusov1, Yulia Isaeva2,3
1Chemistry Department, Lomonosov Moscow State University, Leninskie gory 1,3, 119991, Moscow, Russia.
ChemMedChem
|January 10, 2025
概括
绿色光线激活了一种新的白金 (IV) 前药物GreenPt,用于精确的癌症治疗. 这种双重作用药物释放西斯和光敏感剂,以最小的光剂量提高治疗效率.
科学领域:
- 生物化学 生物化学
- 材料科学 材料科学 材料科学
- 在瘤学瘤学.
背景情况:
- (IV) 预制药提供了与化疗相比的时空控制.
- 将化疗与光动力疗法 (PDT) 结合起来,可以克服个体治疗的局限性.
研究的目的:
- 开发一种绿灯激活的Pt(IV) 前药物 (GreenPt),结合化疗和PDT.
- 为了研究光诱导的思普拉丁释放机制,并评估其光毒性.
主要方法:
- 合成和描述GreenPt前药物.
- 绿光照射研究,用于释放西斯.
- 密度功能理论 (DFT) 建模和光诱导电子转移 (PET) 估计.
- 在体外光毒性测定.
主要成果:
- 在低剂量绿光 (1 J/cm2) 下,GreenPt会释放西斯丁.
- DFT和PET分析确定了光诱导的电子转移作为关键释放机制.
- 基于BODIPY的光敏剂表现出高的光毒性 (PI > 1300).
- 绿色Pt显示光诱导的光毒性 (PI>100) 和细胞内积累.
结论:
- GreenPt是一种高效的绿光激活前药物,用于双作用癌症治疗.
- 这项研究阐明了Pt(IV) 前药物中光诱导的西斯释放机制.
- 通过控制释放西斯和光敏感剂,GreenPt显示出具有协同疗效的潜力.
更多相关视频
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
3.0K
05:13LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation
Published on: January 24, 2025
250
相关概念视频
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...